KLOW Peptide Blend

Key points

• KLOW is a brand style name for a blend, usually KPV, GHK-Cu, BPC-157 and TB-500.
• It brings together peptides marketed for inflammation, skin and tissue repair.
• None of the components is licensed in the UK as an injectable medicine.
• The repair peptides are on the WADA Prohibited List.

Quick facts

What it is

Blend, usually KPV, GHK-Cu, BPC-157 and TB-500

Marketed for

Skin, gut and recovery

UK status

Not a licensed medicine; sold for research use

In sport

Repair peptide components prohibited

How it works

The blend combines an anti inflammatory peptide (KPV), a copper peptide (GHK-Cu) and two repair peptides (BPC-157 and TB-500). Each is covered in its own entry, where the evidence and its limits are set out.

What the evidence shows

There is no evidence for KLOW as a specific product. The components have mostly animal, laboratory or cosmetic evidence individually, and there are no human trials of the combination.

What it does not settle

• There are no human trials of this blend.
• The exact contents of a given vial are uncertain.
• Long term safety of the combination is unknown.

Side effects

Less common but serious

• The risks are those of the individual components, with the added uncertainty of what a blended product contains.
• Because there is no licensed product, the dose, purity and contents of material bought online cannot be verified.

Report any suspected side effect through the MHRA Yellow Card scheme.

UK legal status and access

KLOW has no UK marketing authorisation, so it is not a licensed medicine and is not offered by registered clinics or pharmacies. It is sold online for research use.

Common questions